Magnesium Isoglycyrrhizinate
Chronic Hepatitis B Virus Infection
CttqUNKNOWNPhase 4 / ApprovedDormant
BB
65/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 50/ 100
- Competitive Position
- 89/ 100
Competitive context
11 Active assets in the Chronic Hepatitis B Virus Infection cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Entecavir Beijing Continent Pharmaceutical Co, Ltd. | Phase 4 | BBB |
Lamivudine Yonsei University | Phase 4 | BBB |
Tenofovir Disoproxil Fumarate Ningbo No.2 Hospital | Phase 4 | BBB |
Telbivudine The Fifth People's Hospital of Suzhou | Phase 4 | BBB |
Adefovir Dipivoxil Asian-Pacific Alliance of Liver Disease, Beijing | Phase 4 | BB |
View all 25 →
Same molecule, other indications
Magnesium Isoglycyrrhizinate is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →